270 related articles for article (PubMed ID: 1361881)
1. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
2. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
3. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
Nomi S; Naito K; Kahan BD; Pellis NR
Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
[TBL] [Abstract][Full Text] [Related]
4. Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma.
Naito K; Oka T; Nomi S; Yamagishi H; Kahan BD
Jpn J Cancer Res; 1989 Nov; 80(11):1119-26. PubMed ID: 2514172
[TBL] [Abstract][Full Text] [Related]
5. Specific chemoimmunotherapy in tumor-bearing mice with extracted antigen, cyclophosphamide, and intrasplenic administration of interleukin-2.
Kahan BD; Nomi S; Pellis NR
Cancer; 1986 Feb; 57(3):477-83. PubMed ID: 3484658
[TBL] [Abstract][Full Text] [Related]
6. Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide.
Nomi S; Pellis NR; Kahan BD
J Natl Cancer Inst; 1984 Oct; 73(4):943-50. PubMed ID: 6237215
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
Roberts LK
J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of 1-butanol-extracted murine tumor-specific transplantation antigens.
LeGrue SJ; Pellis NR; Riley LB; Kahan BD
Cancer Res; 1985 Jul; 45(7):3164-72. PubMed ID: 2408745
[TBL] [Abstract][Full Text] [Related]
11. Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones.
Naito K; Pellis NR; Kahan BD
Cell Immunol; 1988 Jan; 111(1):216-34. PubMed ID: 3257414
[TBL] [Abstract][Full Text] [Related]
12. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
13. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM
J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of anti-Pichinde virus cytotoxic T cell memory by cyclophosphamide and restoration by coinfection or interleukin 2.
Walker CM; Paetkau V; Rawls WE; Rosenthal KL
J Immunol; 1985 Aug; 135(2):1401-7. PubMed ID: 2989365
[TBL] [Abstract][Full Text] [Related]
15. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
17. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
18. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
19. Generation of antigenic variants from a nonantigenic murine tumor cell line by transfection with a gene encoding a novel tumor-specific transplantation antigen.
Kaba DS; McIntyre BW; Kripke ML; Goodenow RS; Schreiber H; Ananthaswamy HN
Cancer Res; 1989 Jan; 49(1):38-43. PubMed ID: 2783244
[TBL] [Abstract][Full Text] [Related]
20. Expansion of tumor-specific cytolytic T lymphocytes using in vitro restimulation with tumor-specific transplantation antigen.
Naito K; Pellis NR; Kahan BD
Cell Immunol; 1987 Sep; 108(2):483-94. PubMed ID: 3113743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
